Layoffs loom as Takeda trims early-stage efforts in AAV gene therapy, rare hematology

Takeda is moving away from early-stage R&D work in adeno-associated virus-based gene therapies and the rare hematology spaces, with an unknown number of employees set to “transition out” of the pharma.